Loading clinical trials...
Loading clinical trials...
A Prospective, Randomized, Placebo-controlled, Multicenter, International Phase I/II Trial of RAD001 (Everolimus) in Combination With DHAP as Induction Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Conditions
Interventions
DHAP
Everolimus
Locations
1
Germany
1st Dept. of Medicine, Cologne University Hospital
Cologne, Germany
Start Date
August 1, 2012
Primary Completion Date
March 1, 2019
Completion Date
March 1, 2019
Last Updated
November 8, 2019
NCT05529069
NCT06189391
NCT05006716
NCT06026319
NCT05442515
NCT06745076
Lead Sponsor
University of Cologne
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions